CDC-RFA-JG-26-0130: Improving regional capacity to respond to HIV, TB, and other global health priorities in Central America
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control-GHC notices from 2026.
Centers for Disease Control-GHC offered grants to any type of organization. It expected to make about 2 awards. Applications closed on August 31, 2026.
From the official notice on Grants.gov, last changed July 31, 2026. Checked November 7, 2026.
- Expected awards2
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | July 31, 2026 |
|---|---|
| Deadline | August 31, 2026 |
| Archived by Grants.gov | September 30, 2026 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Is this a realistic fit?
- Most of the program's money (62% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $20,000,000 for Year 1, subject to the availability of funds. You will advance progress towards achieving the 95-95-95 targets and continue to transition site-level support to local governments in Central America (CA) for:El Salvador. Guatemala. Honduras. Nicaragua. Panama. To achieve the goals of this NOFO, you will address gaps in:HIV prevention. Diagnosis. Life-saving treatment. Proposed activities should facilitate country ownership while improving local capacity to:Make sure HIV prevention is available for populations most at risk, through the Sentinel Surveillance of STI and HIV Strategy (VICITS).Provide testing that leads to active linkage to HIV treatment and prevention services. Improve early HIV diagnosis through active case-finding strategies, including:Testing as outreach for populations most at risk for HIV.Index, provider-initiated, and community testing. Social network strategy. Self-testing. Support the integration of comprehensive care and treatment services, including for HIV, TB, and other opportunistic infections. Build capacity of healthcare workers to provide high-quality health services led by the country, and through continuous quality improvement (CQI) initiatives. Make sure adequate data systems are used to monitor progress toward 95-95-95 targets and other global health priorities. Support sustainable health systems that improve:Efficiency. Country ownership of the program. Global health security to fight priority infectious diseases and other public health threats.
Who has won Global AIDS grants before
From fiscal 2021 to 2025, Global AIDS (93.067) awarded $7.6 billion across 521 grant awards, an average of $14.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of Columbia University in the City of New York | New York | 32 | $684 million |
| Elizabeth Glaser Pediatric AIDS Foundation | District of Columbia | 13 | $387 million |
| Management and Development for Health | 5 | $282 million | |
| Apin Public Health Initiatives LTD/Gte | 4 | $209 million | |
| University of Washington | Washington | 8 | $195 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-JG-26-0130 still open?
No. It closed on August 31, 2026.
Who can apply for Improving regional capacity to respond to HIV, TB, and other global health priorities in Central America?
Centers for Disease Control-GHC accepted applications from any type of organization.
What is the deadline for Improving regional capacity to respond to HIV, TB, and other global health priorities in Central America?
Closed August 31, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has won Global AIDS grants before?
The largest recipients over five fiscal years were The Trustees of Columbia University in the City of New York, Elizabeth Glaser Pediatric AIDS Foundation, Management and Development for Health. The program made 521 awards worth $7.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)